Harrow, Inc. (HROW) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Harrow, Inc.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Harrow is a leading provider of ophthalmic disease management solutions in North America, operating through two primary segments: Branded (FDA-approved ophthalmic pharmaceuticals) and ImprimisRx (ophthalmology-focused pharmaceutical compounding). The company markets products for dry eye disease, retinal diseases, and perioperative care.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | Variance |
|---|---|---|---|
| Total Revenues | $272.3 million | $199.6 million | +36.4% |
| Gross Profit | $204.4 million | $150.4 million | +36.0% |
| Operating Income | $30.5 million | $8.8 million | +246.6% |
| Net Loss | $(5.1) million | $(17.5) million | Improvement |
| Cash and Equivalents | $72.9 million | $47.2 million | +54.4% |
| Long-Term Debt (Net) | $243.2 million | $219.5 million | +10.8% |
Segment Performance:
- Branded Revenue: $195.8 million (up 68.6% YoY), driven by significant growth in IHEEZO ($81.3M) and VEVYE ($88.7M).
- ImprimisRx Revenue: $76.5 million (down 8.3% YoY), attributed to volume decreases and product mix shifts.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $72.7 million, primarily due to the commercial success of IHEEZO and VEVYE. Branded revenue now represents 72% of total revenue, up from 58% in 2024.
- Profitability: Operating income improved significantly to $30.5 million from $8.8 million, despite higher operating expenses. Net loss narrowed to $5.1 million from $17.5 million.
- Debt Restructuring: In September 2025, the company issued $250 million in 8.625% Senior Notes due 2030. Proceeds were used to fully repay all prior outstanding debt, including the Oaktree Loan ($107.5M), 2026 Notes ($75M), and 2027 Notes ($40.25M). This resulted in a one-time loss on extinguishment of debt of $7.75 million.
- Acquisition: Completed the acquisition of remaining equity interests in Melt Pharmaceuticals, Inc. in November 2025 for an initial cash payment of ~$4.3 million, plus significant contingent consideration tied to FDA approval and sales milestones for the MELT-300 product candidate.
- Regulatory/Operational: ImprimisRx voluntarily surrendered its California 503B and 503A licenses effective February 1, 2026, following a settlement with the California Board of Pharmacy. The company does not currently view this as material to consolidated operations.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Commercial Launches: Expect to launch BYOOVIZ (LUCENTIS biosimilar) and BYQLOVI (post-op inflammation) in mid-2026. OPUVIZ (EYLEA biosimilar) is expected in mid-2027.
- MELT-300: Phase 3 clinical program completed. NDA submission expected in H1 2027, with potential commercial launch in H2 2028 if approved.
- Sales Force Expansion: Plans to expand the VEVYE sales team from ~50 to 100 territories by late May 2026.
Key Risks and Contingencies:
- Regulatory Compliance: Ongoing FDA oversight of the 503B outsourcing facility in New Jersey. While discussions regarding the 2024 inspection are closed, continued compliance is critical to avoid enforcement actions.
- Reimbursement Pressure: Significant exposure to Medicare Part B inflation rebates and Medicaid rebate programs. Changes in CMS policies or international reference pricing could impact net pricing.
- Debt Service: The new 2030 Notes carry an 8.625% interest rate. The company must maintain a fixed charge coverage ratio of at least 1.10 to 1.0 under its new revolving credit facility.
- Cybersecurity: The company experienced a non-material cybersecurity incident in November 2024 involving unauthorized email access and fund diversion, which was detected and mitigated quickly.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the fixed charge coverage ratio (1.10:1.0) required by the Fifth Third Revolver and the 2030 Notes indenture.
- Reimbursement Rates: Monitor actual vs. estimated government rebate accruals, which totaled $68.4 million in reserves at year-end, as these significantly impact net revenue.
- MELT-300 Milestones: Track progress toward FDA approval and J-code assignment, as these trigger substantial contingent payments (up to $87.2M cash + equity) to Melt shareholders.
- California License Impact: Assess the actual revenue impact of the loss of California compounding licenses in early 2026.
- Product Launch Execution: Confirm the timing and initial uptake of BYOOVIZ and BYQLOVI launches in mid-2026.